In this study, we identified a newly synthesized compound 7o with potent inhibition on EGFR
primary mutants (L858R, Del19) and drug-resistant mutant T790M with nanomolar IC 50 …

Background▪ NSCLC patients having an activating EGFR mutation initially responded well to
EGFR TKI but most of them experienced progressive disease due to various resistance …

Here in, we report the design, synthesis and in vitro anticancer activity of a novel series of 24
quinoline analogues of substituted amide and sulphonamide derivatives. The anticancer …

Introduction: Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations
initially respond well to EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited …

Epidermal growth factor receptor (EGFR) inhibitors have clinical utility in the treatment of non-
small cell lung cancer (NSCLC) patients. Despite encouraging clinical efficacy with these …

Introduction: Activating mutations of EGFR are well known as oncogenic driver mutations in
lung adenocarcinoma. Currently, EGFR TKIs including Gefitinib and Erlotinib are used as …

New substituted quinoline derivatives were designed and synthesized via a five-step
modified Suzuki coupling reaction. A comparative molecular docking study was carried out …

Clinical data acquired over the last decade on non-small cell lung cancer (NSCLC)
treatment with small molecular weight Epidermal Growth Factor Receptor (EGFR) inhibitors …

The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …

A series of new deuterated and non-deuterated N 2, N 4-diphenylpyridine− 2, 4-diamine
derivatives were synthesized and evaluated as EGFR C797S-mediated resistance …